Edition:
United Kingdom

Denali Therapeutics Announces Positive Clinical Results From LRRK2 Inhibitor Program For Parkinson'S Disease


Wednesday, 1 Aug 2018 

Aug 1 (Reuters) - Denali Therapeutics Inc ::DENALI THERAPEUTICS ANNOUNCES POSITIVE CLINICAL RESULTS FROM LRRK2 INHIBITOR PROGRAM FOR PARKINSON’S DISEASE.DENALI THERAPEUTICS INC - DNL201 WAS GENERALLY WELL TOLERATED WITH NO SERIOUS ADVERSE EVENTS IN STUDY.DENALI THERAPEUTICS INC - DNL201 WILL ADVANCE TO PHASE 1B IN PARKINSON'S DISEASE PATIENTS WITH AND WITHOUT A GENETIC LRRK2 MUTATION.DENALI THERAPEUTICS INC - HEALTHY VOLUNTEER STUDY OF DNL201 MEETS ALL OBJECTIVES IN PHASE 1 CLINICAL STUDY. 

Company Quote

25.17
-1.03 -3.93%
18 Apr 2019